Dyne therapeutics linkedin
WebJan 18, 2024 · Dyne Therapeutics (DYN-5.97%) saw its shares slump 18.1% on Tuesday. The biotech stock closed on Friday at $9.29 a share, then opened on Tuesday at $7.82, falling to a new 52-week low of $7.61 in ... WebJul 5, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to …
Dyne therapeutics linkedin
Did you know?
WebGet the latest Dyne Therapeutics Inc (DYN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. WebApr 2024 - Aug 20245 months. Boston, Massachusetts, United States. Contracted to develop program and commercial strategies for bone health projects and drug programs. Reported to Chief Business ...
WebDyne Therapeutics 2 years 1 month Senior Scientist Dyne Therapeutics Jul 2024 - Present 10 months. Waltham, Massachusetts, United States … WebSenior Clinical Research Associate. PAREXEL. ott 2008 - ott 20102 anni 1 mese. Sydney, AUSTRALIA.
WebMay 16, 2024 · DYNE-101 is designed to enable targeted delivery to muscle tissue and address the genetic basis of the disease. The new data being presented during ASGCT evaluated monthly repeat doses of DYNE-101 ... WebJan 18, 2024 · WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed on …
WebApr 4, 2024 · Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven …
WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … simple simon\u0027s east bernard txWebFeb 9, 2024 · 1 to 50 Employees. Founded: 2024. Type: Company - Public (DYN) Industry: Biotech & Pharmaceuticals. Revenue: Less than $1 million (USD) Competitors: Unknown. simple simon\u0027s huntington txWebApr 11, 2024 · Dyne Therapeutics has a 52-week low of $4.30 and a 52-week high of $15.63. Dyne Therapeutics ( NASDAQ:DYN - Get Rating ) last issued its quarterly earnings data on Thursday, March 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10. raycity rpsimple simon\u0027s nowataWebSep 6, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … simple simon\u0027s hatfield arWebDyne Therapeutics 5 years 3 months Vice President - Head of Platform Development Dyne Therapeutics Feb 2024 - Present 3 months. Waltham, Massachusetts, United States ... raycity rp discordWebAlnylam Pharmaceuticals. Jun 2008 - Jun 20157 years 1 month. Cambridge, MA. Set up group and practices and responsible for running following corporate functions: - Business … simple simon\u0027s east bernard